United Kingdom

At a Glance     Contact

United Kingdom

An Introduction to Ranbaxy in United Kingdom ( UK ) Ranbaxy (U.K.) Ltd. (RUKL) is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. and it plays a significant role in Ranbaxy’s European presence. RUKL has made considerable progress in enhancing its product portfolio and for securing the product basket by in-licensing products. Deals have been signed with various companies, for a number of different molecules in different therapeutic areas. These are over and above the in-house product pipeline and give further impetus to RUKL's growth in the UK pharmaceuticals market.   Our Key Strengths   A wide generics portfolio Robust product pipeline Vertically integrated in major molecules Research and Development An experienced, successful, talented team, committed to success and Ranbaxy’s global values   RUKL at a Glance   Date of Incorporation November, 1994 Ranbaxy Sales US $ 38 Mn (2008) Total No. of Molecules Ranbaxy +Local tie ups 75 Key Products Simvastatin, Venlafaxine, Risperidone, Pravastatin, Gabapentin, Lansoprazole, Lisinopril Presence in Therapeutic Segments Metabolic, Anti-Infectives, Cardiovasculars, Central Nervous System, Respiratory